Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$14.9 million.

  • Orchestra BioMed Holdings' Free Cash Flow fell 793.14% to -$14.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 2619.46%. This contributed to the annual value of -$50.8 million for FY2024, which is 1004.65% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Free Cash Flow stood at -$14.9 million for Q3 2025, which was down 793.14% from -$15.6 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Free Cash Flow high stood at -$5.4 million for Q1 2022, and its period low was -$16.7 million during Q1 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' median Free Cash Flow value was -$11.0 million (recorded in 2023), while the average stood at -$11.6 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first tumbled by 16840.44% in 2023, then skyrocketed by 828.94% in 2024.
  • Orchestra BioMed Holdings' Free Cash Flow (Quarter) stood at -$8.8 million in 2022, then decreased by 24.7% to -$11.0 million in 2023, then fell by 24.36% to -$13.6 million in 2024, then dropped by 8.91% to -$14.9 million in 2025.
  • Its last three reported values are -$14.9 million in Q3 2025, -$15.6 million for Q2 2025, and -$16.7 million during Q1 2025.